Summary
Vertex Pharmaceuticals Inc. (VRTX) has entered into a significant credit agreement for a $300 million senior secured term loan, with the potential to increase this by an additional $200 million. This financing is strategically aimed at bolstering the company's financial position to fund its ongoing development programs, particularly in cystic fibrosis, and to support research for future medicines, including potential collaborations. The loan structure includes an initial interest-only period for 12 months, followed by a two-year amortization period with the majority of the principal repayment occurring in the third year. This provides Vertex with flexibility as it advances its promising drug pipeline.
Key Highlights
- 1Secured a $300 million senior secured term loan with an option to increase by $200 million.
- 2Financing intended to support development programs in cystic fibrosis and future drug research.
- 3The loan has a three-year term, maturing on July 9, 2017.
- 4Initial 12-month interest-only period, followed by a two-year amortization period.
- 5Interest rate starts at 7.2% annually, potentially decreasing to 6.2% upon FDA approval of a specific cystic fibrosis treatment for a certain patient group, and then tied to LIBOR plus a margin post-second anniversary.
- 6Loan obligations are guaranteed by domestic subsidiaries and secured by substantially all of Vertex's assets.
- 7Covenants include maintaining minimum KALYDECO net revenues and restrictions on additional debt, liens, and certain corporate actions.
Frequently Asked Questions
The primary purpose of the $300 million senior secured term loan is to strengthen Vertex Pharmaceuticals' financial position, enabling the company to invest in its key development programs, particularly in cystic fibrosis, and to fund research for future medicines, including potential collaborations.
The loan has a three-year term. The first 12 months are interest-only. The subsequent two years involve principal and interest repayment, with the majority of the principal due in the third year. Specific quarterly principal payments are scheduled starting October 1, 2015.
The initial interest rate is 7.2% per annum, with the potential to decrease to 6.2% upon U.S. FDA approval of a product for treating specific cystic fibrosis patients aged 12 and older. After the second anniversary of closing, the rate will be based on LIBOR plus a margin (5.0% to 7.5%) depending on whether the FDA approval condition has been met.
Yes, the credit agreement includes covenants that require Vertex to maintain a minimum level of KALYDECO net revenues. It also imposes restrictions on the company and its subsidiaries regarding incurring additional debt, granting liens, engaging in certain investment or disposition transactions, paying dividends, repurchasing stock, and entering into affiliate transactions.